Finance

Lists
LYEL:NASDAQ
Lyell Immunopharma Inc
$14.32
-4.25%
(-0.64) 1D
$14.32
0.00% (0.00)
After hours
Closed: Sep 3, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LYEL...
Open
$15.11
High
$15.14
Low
$14.19
Mkt. cap
350.80M
Avg. vol.
146.00K
Volume
79.05K
52-wk high
$45.00
52-wk low
$11.21
EPS
-$12.01
Beta
-0.04
Shares outstanding
24.50M
No. of employees
161
Open
$15.11
High
$15.14
Low
$14.19
Mkt. cap
350.80M
Avg. vol.
146.00K
Volume
79.05K
52-wk high
$45.00
52-wk low
$11.21
EPS
-$12.01
Beta
-0.04
Shares outstanding
24.50M
No. of employees
161
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitelyell.com
Analyst ratings
Based on 5 analysts giving stock ratings to LYEL in the past 3 months
Buy
Buy
4
Hold
0
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for LYEL in the last 3 months.
Highest
Current $14.32
$45.00 (+214.25%)
Average
$36.20 (+152.79%)
Lowest
$12.00 (-16.20%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$36.00
+151.4%
08/14/2026
Jason Zemansky
Bank of America Securities
Sell
Reiterated
$12.00
-16.2%
08/11/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$45.00
+214.2%
08/07/2026
Gil Blum
Needham
Buy
Maintained
$44.00
+207.3%
08/07/2026
Yuan Zhi
B. Riley Securities
Buy
Initiated
$44.00
+207.3%
07/22/2026
Jack Allen
Robert W. Baird
Buy
Initiated
$49.00
+242.2%
05/01/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$34.00
+137.4%
03/09/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.74 / -$1.79
+2.87%beat
Revenue / Est. (USD)
4.00K / 3.29K
+21.58%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.00K
6.00K
2.00K
4.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
28.17M
52.20M
36.60M
39.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.69M
10.62M
9.56M
9.58M
Operating expense
37.27M
61.48M
44.26M
47.34M
Total operating expenses
37.27M
61.48M
44.26M
47.34M
Operating income
-37.25M
-61.48M
-44.26M
-47.34M
Other non operating income
-4.86M
-17.46M
17.91M
398.00K
EBT including unusual items
-38.85M
-140.72M
-24.15M
-44.76M
EBT excluding unusual items
-38.85M
-76.26M
-24.15M
-44.76M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-1.59M
-1.33M
-1.90M
-1.76M
Net income
-38.85M
-140.72M
-24.15M
-44.76M
Net profit margin
-258,973.33%
-2,345,383.33%
-1,207,650.00%
-1,118,875.00%
Earnings per share
-
-
-
-1.74
Interest and investment income
3.27M
2.68M
2.19M
2.18M
Interest expense
-
-
-
-
Net interest expenses
3.27M
2.68M
2.19M
2.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.69M
-59.08M
-41.93M
-45.12M
Gain or loss from assets sale
-249.00K
-166.00K
-
117.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps